/Investor DB

Elevate Ventures — 2018 Investments

9 investments dated 2018 · listed companies and verified rows first · show all

Confluence Pharmaceuticalsconfluencepharma.comSep 2018

Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders.

BiotechDigital HealthCarmel, US

Steven L. Johns(President & Founder)

BoardBoyd W. Sturdevant, Jr.(Chairman & Founder)

Board seatPhil Lodato· per SEC Form D

Co-investorsIU Ventures

Atlas 3Dsiemens.comJan 2018

Siemens provides industrial products, services and software spanning the industrial lifecycle, using AI, simulation and smart technologies for digital transformation.

Advanced ManufacturingAI & Machine LearningEnterprise SoftwareIoTMunich, DE

Co-investorsAnzu PartnersHarmony Partners

Invoke Learninginvokelearning.comin𝕏Dec 2018

Invoke Learning builds InvokeClarity, a data lakehouse for higher education, along with a suite of analytics applications and AI-enhanced dashboards.

AI & Machine LearningData & InfrastructureEdTechSaaSIndianapolis, US

Brendan Aldrich(Executive Officer, Director)Lige Hensley(Executive Officer, Director)

Co-investorsSandalphon CapitalFlywheel Fund

Ironcladironcladapp.comin𝕏Sep 2018

Ironclad is an AI platform for digital contract management that helps companies execute faster deals, reduce contract surprises, and measure value.

AI & Machine LearningEnterprise SoftwareLegalTechSaaSSan Francisco, US

Jason Boehmig(CEO)inBrian Powers(Executive Officer)Cai GoGwilt(CTO)Jason Springer(Chief Executive Officer)Jeremy Smith(President)inVedavati Verma(Chief Technology Officer)

Co-investors500 GlobalAccelAmplo VenturesBetter Tomorrow VenturesBond Capital ManagementCowboy Ventures+33 more

Nanovisnanovistechnology.cominAug 2018 · $5.5M

Nanovis develops and manufactures nanoscale surface technologies designed to improve the integration of orthopedic, spinal, and dental implants.

BiotechMedical DevicesNew MaterialsColumbia City, US

Matthew Hedrick(Chief Executive Officer and President)Brian More(Chief Financial Officer)in

BoardBrian Emerick(Chairman of Board)Steve Gerrish(Board Member)

On Target Laboratoriesontargetlabs.comin𝕏Mar 2018

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.

BiotechHealthtechMedical Devices

Bill Peters(President, Chief Executive Officer, and Board Member)inRod MacLeod(Chief Financial Officer)inTommy Lee(Senior Vice President of Clinical Operations)inCatherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)inScott Huennekens(Executive Chairperson)in

Co-investors3B Future Health FundCerity Partners VenturesH.I.G. CapitalH.I.G. HealthBridge PartnersH.I.G. BioHealth Partners

Scioto Biosciencessciotobiosciences.cominApr 2018 · $2M

Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana.

BiotechDeep TechDigital HealthIndianopolis, US

Joe Trebley(Founder & Chief Executive Officer)inJim Schulz(Founder & Chief Financial Officer)inMark Heiman(Chief Science Officer)inKevin Meyer(Chief Operating Officer)in

Co-investorsIU VenturesMichigan Capital NetworkPathway BioventuresBioCrossroadsRev1 Ventures

Springbukspringbuk.comin𝕏Jan 2018 · $20M

Springbuk provides a health data analytics platform that helps benefit leaders analyze employee health claims data to guide healthcare decision-making and benefit strategy.

Data & InfrastructureDigital HealthHealthtechSaaS

Co-investorsLewis & Clark VenturesMultiplier CapitalEcho Health VenturesHealthQuest Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Tendly

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.